Expert Analysis

Updates in HCV Treatment

Source: CCO Official Conference Coverage of the 2009 Annual Meeting of the American Association for the Study of Liver Diseases*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Updates in HCV Treatment

Faculty:

Michael P. Manns, MD
David R. Nelson, MD
Tram T. Tran, MD

CREDIT INFORMATION

Release Date: 12/30/09

Expiration Date: 12/29/10

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Cite new phase II data on the safety and efficacy of protease inhibitors used in combination with standard peginterferon/ribavirin therapy for treatment-naive and treatment-experienced patients with genotype 1 HCV infection
Summarize recent findings on predictors of response to peginterferon/ribavirin therapy among patients infected with genotype 1 HCV
Articulate the latest clinical trial results on the safety, efficacy, and resistance profile of combination HCV therapy with HCV protease and polymerase inhibitors
Describe emerging new data on the safety and efficacy of novel HCV polymerase inhibitors

Topics covered include:

SILEN-C1: BI 201335 and Peginterferon alfa-2a/Ribavirin in Treatment-Naive Patients With Genotype 1 HCV
NEXT-1: Narlaprevir Plus Peginterferon alfa-2b/Ribavirin in Treatment-Naive Patients With Genotype 1 HCV
Study C208: Less Frequent Telaprevir Dosing in Combination With Peginterferon alfa-2a vs Peginterferon alfa-2b Plus Ribavirin
Telaprevir Plus Peginterferon alfa-2a/Ribavirin in Treatment-Naive Patients With Genotype 1 HCV and Poor Prognostic Indicators
Genetic Predictors of Response to Peginterferon/Ribavirin in the IDEAL Trial: IL-28B–Linked Polymorphism
Efficacy of Boceprevir Plus Peginterferon alfa-2b/Ribavirin in Null Responders to Peginterferon alfa-2b/Ribavirin: Retrospective Analysis of SPRINT-1
Final PROVE 3 Results and the Use of Response-Guided Therapy With Protease Inhibitors
Early-Phase Studies of Novel Polymerase Inhibitors
INFORM-1: Combination Therapy With Direct-Acting Antiviral Agents RG7128 and RG7227 in Patients With Genotype 1 HCV
Thymosin alpha-1 Plus Peginterferon alfa-2a/Ribavirin in Treatment-Experienced Patients
Impact of Higher-Dose Ribavirin on SVR
T-Cell–Based Anti-HCV Vaccines for Prevention and Treatment of HCV Infection
Pioglitazone Plus Peginterferon alfa-2a/Ribavirin in Patients With Genotype 1 HCV Infection and Insulin Resistance

Abstract

Click here to view abstract

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.